Heba M. El-Bosily, Khaled R. Abd El Meguid, Nagwa A. Sabri, Marwa Adel Ahmed
{"title":"临床药师领导的抗凝管理计划:提高医生对循证指南的依从性,减少抗凝相关药物错误","authors":"Heba M. El-Bosily, Khaled R. Abd El Meguid, Nagwa A. Sabri, Marwa Adel Ahmed","doi":"10.1186/s43094-025-00791-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Due to their high risk of medication errors (MEs) and the potentially devastating thrombotic and bleeding events, anticoagulants are a class of high-risk medications that require regular monitoring by healthcare professionals. The pharmacist is in the ideal position to provide patient care during anticoagulation therapy which is still prone to inappropriate prescribing. The pharmacist is capable of anticoagulation therapy monitoring, provision of drug information, dosing protocol preparation, drug interaction screening, and educating patients. It has been demonstrated that specialized anticoagulation management programs enhance clinical safety and quality of anticoagulant therapy. This study aimed to evaluate the effect of implementing a pharmacist-led anticoagulation stewardship program in reducing anticoagulant-related MEs. We conducted a prospective pre-and post-intervention study in a tertiary hospital on 233 patients with 4132 anticoagulant doses to assess the impact of this program implementation.</p><h3>Results</h3><p>This study found that MEs were significantly reduced after implementing the anticoagulation stewardship program. Specifically, the “Medication without indication” and the “Incorrect dose (low dose)” types of MEs were remarkably decreased from 14.4% pre- to 3.3% post-, and from 47.6% pre- to 28.7% post-implementation, respectively. Interestingly, the “Wrong route” disappeared in the post-implementation phase of the study. The proportion of wrong doses/total doses decreased from 0.474 ± 0.044 to 0.432 ± 0.04 (<i>p</i> = 0.003), while category F decreased from 8.3% to 4.7% (<i>p</i> = 0.001). Physician adherence to evidence-based guidelines (EBG) improved as full adherence increased from 38.8 to 60.2% (<i>p</i> = 0.001) and non-adherence decreased from 26.7 to 3.4% (<i>p</i> = 0.001). These statistically significant findings further suggest valuable clinical benefits since implementing this pharmacist-led program could improve patient outcomes by reducing ME and increasing physician adherence to EBG guidelines.</p><h3>Conclusions</h3><p>Although the study was limited by the hospital clinical pharmacist team's working hours, as they work 12 h/day rather than 24, and hence, the program was only observed during this time, the study concluded that the anticoagulation stewardship program encouraged the safe use of anticoagulants, lessened MEs and their severity, and improved physician adherence to EBG. Future studies should assess the effect of such programs on other clinical outcomes beyond MEs and determine their impact on healthcare costs.</p><p><i>Clinical Trial registration</i>: Clinicaltrials.gov: NCT03812848. Date: January 1, 2018.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00791-w","citationCount":"0","resultStr":"{\"title\":\"Clinical pharmacist-led anticoagulation stewardship program: improve physician adherence to evidence-based guidelines and reduce anticoagulant-related medication errors\",\"authors\":\"Heba M. El-Bosily, Khaled R. Abd El Meguid, Nagwa A. Sabri, Marwa Adel Ahmed\",\"doi\":\"10.1186/s43094-025-00791-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Due to their high risk of medication errors (MEs) and the potentially devastating thrombotic and bleeding events, anticoagulants are a class of high-risk medications that require regular monitoring by healthcare professionals. The pharmacist is in the ideal position to provide patient care during anticoagulation therapy which is still prone to inappropriate prescribing. The pharmacist is capable of anticoagulation therapy monitoring, provision of drug information, dosing protocol preparation, drug interaction screening, and educating patients. It has been demonstrated that specialized anticoagulation management programs enhance clinical safety and quality of anticoagulant therapy. This study aimed to evaluate the effect of implementing a pharmacist-led anticoagulation stewardship program in reducing anticoagulant-related MEs. We conducted a prospective pre-and post-intervention study in a tertiary hospital on 233 patients with 4132 anticoagulant doses to assess the impact of this program implementation.</p><h3>Results</h3><p>This study found that MEs were significantly reduced after implementing the anticoagulation stewardship program. Specifically, the “Medication without indication” and the “Incorrect dose (low dose)” types of MEs were remarkably decreased from 14.4% pre- to 3.3% post-, and from 47.6% pre- to 28.7% post-implementation, respectively. Interestingly, the “Wrong route” disappeared in the post-implementation phase of the study. The proportion of wrong doses/total doses decreased from 0.474 ± 0.044 to 0.432 ± 0.04 (<i>p</i> = 0.003), while category F decreased from 8.3% to 4.7% (<i>p</i> = 0.001). Physician adherence to evidence-based guidelines (EBG) improved as full adherence increased from 38.8 to 60.2% (<i>p</i> = 0.001) and non-adherence decreased from 26.7 to 3.4% (<i>p</i> = 0.001). These statistically significant findings further suggest valuable clinical benefits since implementing this pharmacist-led program could improve patient outcomes by reducing ME and increasing physician adherence to EBG guidelines.</p><h3>Conclusions</h3><p>Although the study was limited by the hospital clinical pharmacist team's working hours, as they work 12 h/day rather than 24, and hence, the program was only observed during this time, the study concluded that the anticoagulation stewardship program encouraged the safe use of anticoagulants, lessened MEs and their severity, and improved physician adherence to EBG. Future studies should assess the effect of such programs on other clinical outcomes beyond MEs and determine their impact on healthcare costs.</p><p><i>Clinical Trial registration</i>: Clinicaltrials.gov: NCT03812848. Date: January 1, 2018.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00791-w\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00791-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00791-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Clinical pharmacist-led anticoagulation stewardship program: improve physician adherence to evidence-based guidelines and reduce anticoagulant-related medication errors
Background
Due to their high risk of medication errors (MEs) and the potentially devastating thrombotic and bleeding events, anticoagulants are a class of high-risk medications that require regular monitoring by healthcare professionals. The pharmacist is in the ideal position to provide patient care during anticoagulation therapy which is still prone to inappropriate prescribing. The pharmacist is capable of anticoagulation therapy monitoring, provision of drug information, dosing protocol preparation, drug interaction screening, and educating patients. It has been demonstrated that specialized anticoagulation management programs enhance clinical safety and quality of anticoagulant therapy. This study aimed to evaluate the effect of implementing a pharmacist-led anticoagulation stewardship program in reducing anticoagulant-related MEs. We conducted a prospective pre-and post-intervention study in a tertiary hospital on 233 patients with 4132 anticoagulant doses to assess the impact of this program implementation.
Results
This study found that MEs were significantly reduced after implementing the anticoagulation stewardship program. Specifically, the “Medication without indication” and the “Incorrect dose (low dose)” types of MEs were remarkably decreased from 14.4% pre- to 3.3% post-, and from 47.6% pre- to 28.7% post-implementation, respectively. Interestingly, the “Wrong route” disappeared in the post-implementation phase of the study. The proportion of wrong doses/total doses decreased from 0.474 ± 0.044 to 0.432 ± 0.04 (p = 0.003), while category F decreased from 8.3% to 4.7% (p = 0.001). Physician adherence to evidence-based guidelines (EBG) improved as full adherence increased from 38.8 to 60.2% (p = 0.001) and non-adherence decreased from 26.7 to 3.4% (p = 0.001). These statistically significant findings further suggest valuable clinical benefits since implementing this pharmacist-led program could improve patient outcomes by reducing ME and increasing physician adherence to EBG guidelines.
Conclusions
Although the study was limited by the hospital clinical pharmacist team's working hours, as they work 12 h/day rather than 24, and hence, the program was only observed during this time, the study concluded that the anticoagulation stewardship program encouraged the safe use of anticoagulants, lessened MEs and their severity, and improved physician adherence to EBG. Future studies should assess the effect of such programs on other clinical outcomes beyond MEs and determine their impact on healthcare costs.
Clinical Trial registration: Clinicaltrials.gov: NCT03812848. Date: January 1, 2018.
期刊介绍:
Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.